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Background: To investigate the therapeutic effect of p38-MAPK inhibitor, SB203580, on dry eye in a mouse model
of Sjögren’s syndrome (MRL/lpr mice).
Methods: 18 female BALB/c mice and 44 female MRL/lpr mice were included. Mice were randomly assigned to
the control or treatment group. The expression of phospho-p38 MAPK in lacrimal glands of BALB/c mice was
determined by Western blot analysis following IL-1β treatment at various time points. Different doses of SB203580 were
injected into lacrimal glands of MRL/lpr mice and phenol red thread test was performed seven days post-injection.
Moreover, the levels of acetylcholine and norepinephrine expression in lacrimal glands of MRL/lpr mice were measured
using spectrofluoremetric assay and the histopathology of lacrimal glands was also evaluated.
Results: The expression of p-p38 MAPK in lacrimal glands of BALB/c mice gradually increased following incubation
with IL-1β ex vivo. Injection of SB203580 into lacrimal glands significantly improved the results of phenol red thread test
in MRL/lpr mice. In addition, the secretions of acetylcholine and norepinephrine increased significantly compared to
the control group. Less lymphocytes infiltration was observed in pathological section of lacrimal glands following
SB203580 injection.
Conclusions: Our results indicate that the activation of p38-MAPK pathway plays an important role in dry eye of a
Sjögren’s syndrome mouse model. Inhibition of p38-MAPK pathway by SB203580 might have potential therapeutic
effect on Sjögren’s syndrome associated dry eye.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1256849631103092.
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The International Dry Eye WorkShop (DEWS) updated
the definition of dry eye in 2007 [1], which reads as follows
“Dry eye is a multifactorial disease of the tears and ocular
surface that results in symptoms of discomfort, visual dis-
turbance, and tear film instability with potential damage
to the ocular surface. It is accompanied by increased osmo-
larity of the tear film and inflammation of the ocular
surface.” Inflammation was especially highlighted in this
new definition.* Correspondence: zoujun70@126.com; zhanghusts@163.com
†Equal contributors
2Department of Ophthalmology, Shanghai Jiao Tong University Affiliated
Sixth People’s Hospital, Shanghai, China
3Institute of Arthritis Research, Shanghai Academy of Chinese Medical
Sciences, Shanghai, China
Full list of author information is available at the end of the article
© 2014 Ma et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orA deficiency in secretions of lacrimal and salivary
glands is the primary cause of dry eye and dry mouth,
and Sjögren’s syndrome is the leading cause of the aque-
ous tear-deficient dry eye [2,3]. Sjögren’s syndrome is an
autoimmune disease that occurs almost exclusively in fe-
males (about 90%). This syndrome is associated with an
extensive lymphocytic infiltration of the lacrimal and sal-
ivary glands and destruction of epithelial cells. To date
there is no cure for this disease. Moreover, the exact
cause of Sjögren’s syndrome is largely unknown but may
involve numerous factors including those of viral, endo-
crine, neural, genetic, and environmental origin [4-6].
Reflexes from ocular surface and optic nerve, as well as
from higher centers of the brain, stimulate lacrimal gland
secretion through parasympathetic and sympathetic effer-
ent pathways [7-9]. Parasympathetic and sympathetic. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sels of the lacrimal and salivary glands. The parasympa-
thetic nerves contain the neurotransmitter acetylcholine,
which acts through cholinergic muscarinic receptors, and
vasoactive intestinal peptide. Sympathetic nerves contain
norepinephrine, which acts through adrenergic receptors.
The study of Zoukbri et al. showed that stimulation of
nerves from inflamed, but not those from noninflamed,
lacrimal and salivary glands with high concentration of
KCl failed to increase the release of acetylcholine. More-
over, they also found that the activation of noninflamed
lacrimal gland nerves with high KCl resulted in protein
secretion whereas activation of inflamed glands did not.
These findings demonstrate that, as suggested earlier by
Sullivan, inflammation of exocrine glands in Sjögren’s
syndrome results in impaired release of neurotransmitters
from nerves, which leads to decreased fluid secretion.
Several studies have shown that suppression of acetyl-
choline and norepinephrine release from myenteric nerves
was mediated by proinflammatory cytokines including
interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-
α [10-12]. IL-1β was implicated in blocking KCl-induced
norepinephrine release from the myenteric plexus. IL-1β
has also been shown to decrease the acetylcholine level in
rat hippocampal formation. Zoukhri’s study [13] showed
that the levels of proinflammatory cytokines were elevated
in lacrimal and salivary glands of Sjögren’s syndrome pa-
tients as well as in animal models. Moreover, they found
that the protein level of IL-1β was increased in the lacri-
mal and salivary glands of MRL/lpr mice which represents
a mouse model of Sjögren’s syndrome in a disease-
dependent manner.
The MRL/lpr mice and congenic MRL/Mp-lpr/lpr mice
firstly described by Murphy were used as animal models
to study another autoimmune disease, systemic lupus
erythematosus. Later, it was found that these animals had
coexisting Sjögren’s syndrome. NZB/NZW and MRL/lpr
mice show spontaneous development of mononuclear cell
infiltration of the salivary and lacrimal glands and other
organs. In both animals, this disease occurs almost exclu-
sively in females and progresses in an age-dependent man-
ner. MRL/lpr mice, compared to NZB/NZW mice, have
more pronounced and destructive mononuclear infiltra-
tions in lacrimal and salivary glands [14].
The p38 mitogen-activated protein kinase (MAPK)
pathway has been shown to be activated by IL-1β treat-
ment in a number of cell types including lacrimal gland
cells [15]. In this study, consistent with previous observa-
tion, we found that ex vivo incubation of normal lacrimal
glands from BALB/c mice with IL-1β could activate the
p38 MAPK pathway. We report here that administration
of p38 MAP kinase inhibitor SB203580 in lacrimal glands
of a Sjögren’s syndrome mouse model significantly allevi-




18 female BALB/c mice (15–20 weeks old) and 44 female
MRL/lpr mice (18 weeks old, SPF) were purchase from
Shanghai Laboratory Animal Center, Chinese Academy of
Sciences. They were maintained in constant temperature
rooms with fixed light–dark intervals of 12 hours’ length.
All experiments were approved by the Research Ethics
Board of Shanghai Jiao Tong University Affiliated Sixth
People’s Hospital and Shanghai Guanghua Integrative
Medicine Hospital and performed in accordance with the
ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research.
Chemicals
Acetylcholine assay kit, SB203580, recombinant mouse
IL-1β, Krebs-ringer bicarbonate buffer (KRB) were
purchased from Sigma (St. Louis, MO), Phospho-p38
MAP Kinase antibody was purchased from Cell Signal-
ing Technology. Norepinephrine assay kit was ordered
from Alpco.
Western blot analysis of phospho-p38 MAPK in
lacrimal glands
Lacrimal glands were removed from 15-20-week-old
BALB/c. Tissue was cut into small lobules (2 mm in diam-
eter), and incubated at 37°C in KRB buffer (pH 7.4) con-
taining 10 ng/ml IL-1β for 0, 5, 10, 30, 60 and 120 min.
Lobules were subjected to gentle pipetting through tips of
decreasing diameter. The preparation was then filtered
through nylon mesh (150 μm), and the acini were pelleted
by centrifugation (50 g, 2 min). The pellet was washed
through KRB containing 4% BSA by centrifugation (50 g,
2 min). To remove lymphocytes, acini were subjected to a
Ficoll gradient of 2%, 3%, and 4%. Dispersed acini were
allowed to recover for 30 min in fresh KRB buffer contain-
ing 0.5% BSA, after which they were homogenized in
0.3 mL of 10 mM Tris–HCl (pH 7.0). For Western blot
analyses, equal amounts of total protein from acinar cell
lysates were separated on 10% sodium dodecyl sulfate-
polyacrylamide gels, followed by electrotransferred to
nitrocellulose membranes. The phospho-p38 protein was
detected by the p-p38 antibody (dilution, 1:1000).Injection of SB203580 into lacrimal glands
Isoflurane was used to anesthetize MRL/lpr mice.
SB203580 (25 μM, 250 μM, 2.5 mM) or saline in a total
volume of 2 μl was injected into the exorbital lacrimal
glands of anesthetized mice. Injections were performed
once a day for 7 consecutive days [16].
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fluorescein staining
After SB203580 injection into lacrimal glands of MRL/lpr
mice for seven days, phenol red thread test, tear BUT and
fluorescein staining were performed to determine tear
secretion and stability of tear film. Tear production was
measured in lightly anesthetized mice using phenol red
impregnated cotton threads (Zone-Quick, Lacrimedics).
The threads were held with jeweler forceps and applied to
the lateral canthus of both eyes for 10 seconds (Figure 1).
Wetting of the thread (which turns red in contact with
tears) was measured in millimeters under a dissecting
microscope [16]. 0.5 μl of 5% fluorescein sodium was
applied to the murine conjunctival sac. BUT and corneal
staining were observed by slit lamp microscope. The stain-
ing indicates damage of corneal epithelium. The staining
grade was classified by the standard: Grade 0: no staining;
grade 1: 1/8 was stained; grade 2: 1/4 was stained; grade 3:
1/2 was stained; grade 4: > 1/2 was stained.
Assay of acetylcholine and norepinephrine
The amount of acetylcholine and norepinephrine were
measured using the acetylcholine assay kit (Amplex Red;
Molecular Probes) and norepinephrine assay kit (Alpco,
NH, US) according to manufactory’s instruction. This kit
measures the amount of hydrogen peroxide (which in the
presence of horseradish peroxidase leads to the oxidation
of Amplex Red) produced through the oxidation of choline.
For the measurement of acetylcholine, 0.1 ml of media and
tissue homogenate were spotted in duplicate into 96-well
plates. An acetylcholine standard curve was used in each
experiment. In each well, 0.1 ml of assay buffer (50 mM
Tris–HCl, pH 7.5) containing 0.2 M Amplex Red reagent,
2 U/ml horseradish peroxidase, 0.2 U/ml choline oxidase,
and 10 U/ml acetylcholinesterase was added. After incuba-
tion, the fluorescence was determined in a fluorescenceFigure 1 Tear production was measured on lightly anesthetized
mice using phenol red impregnated cotton threads.microplate reader (model FL600; Bio-Tek, Winooski, VT)
using 530 nm excitation wavelength. The concentration of
acetylcholine was determined using the software provided
by the manufacturer (KC4; Bio-Tek). For the measure-
ment of norepinephrine, Pipette 100 μL of samples includ-
ing standards and controls from the Enzyme Plate into the
respective pre-coated norepinephrine microtiter strips.
Then pipette 50 μL of the respective norepinephrine
antiserum into all wells, cover the plate with adhesive foil.
Incubate for 1 min at room temperature (20-25°C) on a
shaker. After incubation for 15 to 20 hours at 4°C, remove
the foil and discard the contents in the wells and wash
each well 4 times thoroughly with 300 μL wash buffer.
Blot dry by tapping the inverted plate on absorbent mater-
ial. Pipette 100 μL of Enzyme Conjugate into all wells.
Then cover the plate with Adhesive Foil and incubate
30 min at room temperature (20-25°C) on a shaker. Re-
move the foil and discard the contents of the wells and
wash each well 4 times thoroughly with 300 μl wash buf-
fer. Blot dry by tapping the inverted plate on absorbent
material. Pipette 100 μl of substrate into all wells, and
incubate 20–30 min at room temperature (20-25°C) on a
shaker. Pipette 100 μl of stop solution into all wells. Finally
read the absorbance of the solution in the wells within
10 min, using a microplate reader set to 450 nm and a
reference wavelength between 620 nm and 650 nm [14].
Lacrimal glands histopathology
Lacrimal glands pieces were fixed in 4% paraformaldehyde
for 24 hours. After incubation in 30% sucrose overnight,
the tissue was frozen in O.C.T. embedding medium. Cryo-
stat sections (6 μm) were placed on gelatin-coated slides
and dried overnight at 37°C. For histopathology experi-
ments, sections were stained with hematoxylin and eosin.
Statistical analysis
The data are presented as mean ± standard deviation
(SD) and number (n). One way analysis of variance
(ANOVA) test was used followed by post hoc test to
determine the significance of variables when comparing
more than 2 groups. Statistical significance is consid-
ered a value of P <0.05. All statistical analyses were
performed using SPSS software, version 10.0.
Results
Effects of IL-1β on p38-MAPK activity in lacrimal glands of
BALB/c mice
Lobules were prepared from lacrimal glands of female
BALB/c mice and incubated for 0–120 minutes (0, 5, 10,
30, 60, and 120 min) with or without IL-1β (10 ng/ml). p38
MAPK activity was determined by western blotting using
an antibody that specifically recognizes the phosphorylated
form of p38 MAPK. As shown in Figure 2, IL-1β induced a
time-dependent activation of p38 MAPK.
Figure 2 Effects of IL-1β on p38 MAPK activity in lacrimal gland of BALB/c mice. Western blot analysis of p-p38 MAPK in lacrimal gland of
BALB/c mice treated with IL-1β (10 ng/ml). The experiment was performed in duplicate with samples from three mice for each time point.
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Female MRL/lpr mice spontaneously develop, in an age-
dependent manner, an autoimmune disease character-
ized by lymphoproliferation, autoantibody formation,
ocular inflammatory lesions, and lacrimal gland disease
and has been widely used as a research model for human
Sjögren’s syndrome dry eye. As mentioned above, the
protein level of IL-1β increased in lacrimal and salivary
glands of MRL/lpr mice, we next tested whether block-
ing IL-1β could modify the disease phenotype. We found
that injection with SB203580, a p38-MAPK pathway in-
hibitor, significantly increased the tear production com-
pared to the vehicle (PBS) injected group (Figure 3A,B).
In parallel studies, we confirmed that there was no dif-
ference in tear production in the vehicle-injected group
compared to the non-injected group. Furthermore, the
corneal epithelium damage by inflammation was allevi-
ated shown by significant decrease of staining grade
(Figure 3C).
Blocking p38 MAPK pathway increased the amount of
acetylcholine and norepinephrine
Secretion of acetylcholine and norepinephrine was de-
tected in lacrimal gland tissue in PBS and SB203580Figure 3 Effect of lacrimal gland injection of SB203580 on tear produ
and spectrofluorometric assay (C) were performed on MRL/lpr mice after in
(n = 8) *P < 0.05, **P < 0.01 compared to controls.injection groups. As shown in Figure 4, both acetylcholine
and norepinephrine secretion increased significantly after
SB203580 injection for 7 days, but not dose dependently.
Lacrimal glands histopathology
In PBS injection group, large quantities of lymphocyte
infiltration were shown, there was a severe inflamma-
tory response with inflammatory cells invading the
interlobular space and surrounding both acinar and
ductal cells (Figure 5A). After injection different con-
centration of SB203580, There was much less inflamma-
tion (Figure 5B).
Discussion
Nowadays the therapies for dry eye in clinic mainly focus
on remission of symptoms, but not aiming at blocking
pathogenesis of this disease [17]. Though cyclosporine eye
drops and steroid hormone which could inhibit immune
response has been developed for the treatment of dry eye,
it could induce impairment of ocular surface defense bar-
rier, secondary infection, and tear secretion. In this study,
we investigated the signal transduction pathway through
which IL-1β inhibited neurotransmitter release from lacri-
mal gland nerves of MRL/lpr mice, a murine model ofction. (A-C) Phenol red thread test (A), tear break up time (BUT) (B),
dicated concentrations of SB203580 were injected for seven days.
Figure 4 Acetylcholine and norepinephrine secretion in different groups. (A,B) Acetylcholine (A) and norepinephrine (B) assays were
performed on MRL/lpr mice after indicated concentrations of SB203580 were injected for seven days. (n = 8) *P < 0.05 compared to controls.
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of p38 MAPK inhibitor SB203580 injection on Sjögren’s
syndrome dry eye, hoping for developing new manage-
ment method in clinic.
Sjögren’s syndrome, together with systemic lupus
erythematosus (SLE), scleroderma, et al., are so-called
autoimmune connective tissue diseases, characterized
by presence of antinuclear antibodies (ANA) in the
blood of patients [18]. A histological hallmark of SLE is
membranous glomerulonephritis, due to immune com-
plex deposition along the glomerular basement mem-
brane. Scleroderma is characterized by progressive
tissue fibrosis, with skin most commonly affected by
edema and perivascular CD4+ and CD8+ lymphocytic
infiltrations. Sjögren’s syndrome is characterized by de-
creased secretion of tears and saliva caused by inflam-
mation of lacrimal and salivary glands. These diseases
are most frequent systemic autoimmune diseases, oc-
curring under a condition in which innate tolerance is
damaged [19].
MRL/lpr mice develop spontaneous autoimmune dis-
ease during aging, which is characterized by lymphocyte
proliferation, autoantibody formation, ocular surfaceFigure 5 Lacrimal gland histopathology of MRL/lpr mice with or with
A, Lacrimal gland from PBS injection group; B, Lacrimal gland from 2500 μinflammation and lacrimal gland inflammation [14]. It is
an animal model widely used in the study of Sjögren’s
syndrome. Large amount of IL-1β could be detected in the
lacrimal gland of MRL/lpr mice, and the level increases
with age, we found that ex vivo incubation of lacrimal
glands isolated from healthy BALB/c mice with IL-1β
resulted in the activated p38MAPK in a time-dependent
manner, suggesting the role of p38 MAPK pathway in
IL-1β-induced inflammation of lacrimal glands.
To test the role of p38 MAPK in vivo, we injected p38
MAPK inhibitor SB203580 into lacrimal gland of MRL/lpr
mice. We found that seven days injection of p38MAPK
inhibitor can significantly improved the disease phenotype
in MRL/lpr mouse model of Sjögren’s syndrome including
increased tear production. This improvement coincides
with increased secretion of neurotransmitters acetylcho-
line and norepinephrine and reduced infiltration of in-
flammatory cells.
In conclusion, in this study, we investigated the role of
the p38MAPK signal transduction pathway in inhibition of
neurotransmitter secretion in lacrimal gland. We demon-
strated the preclinical efficacy of p38-MAPK inhibitor
SB203580 on lacrimal gland secretion and neurotransmitterout SB203580 injection (hematoxylin eosin staining, ×100).
mol/L SB203580 injection group.
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potentially further developed to disease-modifying agent to
prevent and/or treat Sjögren’s syndrome dry eye.
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